MRSN
Mersana Therapeutics, Inc.Company Information
- Company Name
- Mersana Therapeutics, Inc.
- CIK
- CIK0001442836
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- MRSN: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- MRSN
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2025-10-27
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 87,610
Institutional Sentiment
- As of
- 2025-12-31
- Institutional shares owned
- 2,034,083
- Shares outstanding
- 4,992,639
- Ownership
- 40.74%
Earnings Market Reaction
- Filing date
- 2025-11-14
- Price on filing date
- —
- 1-month reaction
- -0.52%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 56 | 77 | 102 | 108 | 79 | 59 | 75 | 175 | 186 | 129 | 123 | 129 | ||||||
| Debt Securities Available For Sale Excluding Accrued Interest | 0 | 0 | 0 | 27 | 76 | 104 | 108 | 35 | 55 | 158 | 151 | 152 | ||||||
| Accounts Receivable Net Current | 0 | 0 | - | - | 1 | 2 | - | 0 | 0 | 0 | 0 | 30 | ||||||
| Prepaid Expense And Other Assets Current | 3 | 3 | 4 | 2 | 4 | 5 | 4 | 5 | 9 | 10 | 8 | 9 | ||||||
| Assets Current | 60 | 80 | 106 | 137 | 161 | 169 | 188 | 214 | 250 | 297 | 282 | 319 | ||||||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 0 | 1 | 2 | 2 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | ||||||
| Operating Lease Right Of Use Asset | 2 | 3 | 4 | 5 | 5 | 6 | 7 | 8 | 8 | 9 | 10 | 10 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Assets | 63 | 85 | 112 | 145 | 170 | 179 | 198 | 226 | 263 | 311 | 296 | 334 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 2 | 3 | 4 | 4 | 2 | 3 | 3 | 7 | 13 | 17 | 18 | 14 | ||||||
| Accrued Liabilities Current | 15 | 15 | 13 | 19 | 19 | 18 | 16 | 22 | 29 | 33 | 33 | 43 | ||||||
| Contract With Customer Liability Current | 24 | 20 | 24 | 22 | 31 | 29 | 26 | 28 | 22 | 21 | 29 | 31 | ||||||
| Operating Lease Liability Current | 2 | 3 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | ||||||
| Long Term Debt Current | 0 | 17 | 13 | 13 | 11 | 8 | 5 | 2 | - | - | - | - | ||||||
| Short Term Borrowings | - | - | - | - | - | - | - | 2 | - | - | - | 0 | ||||||
| Other Liabilities Current | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 43 | 59 | 58 | 62 | 68 | 62 | 53 | 64 | 68 | 75 | 83 | 92 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ||||||
| Long Term Debt | - | - | - | - | - | - | 20 | - | 25 | 25 | 25 | - | ||||||
| Long Term Debt Noncurrent | 0 | 0 | 8 | 11 | 14 | 17 | - | 23 | - | - | - | 25 | ||||||
| Contract With Customer Liability Noncurrent | 79 | 78 | 77 | 79 | 84 | 88 | 92 | 97 | 112 | 114 | 116 | 117 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 122 | 138 | 143 | 154 | 168 | 171 | 170 | 189 | 211 | 221 | 232 | 242 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 892 | 891 | 889 | 886 | 882 | 878 | 874 | 863 | 859 | 855 | 775 | 747 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 0 | 0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -952 | -944 | -920 | -896 | -881 | -870 | -846 | -826 | -807 | -765 | -711 | -655 | ||||||
| Stockholders Equity | -60 | -53 | -31 | -10 | 1 | 8 | 28 | 37 | 52 | 90 | 64 | 92 | ||||||
| Liabilities And Stockholders Equity | 63 | 85 | 112 | 145 | 170 | 179 | 198 | 226 | 263 | 311 | 296 | 334 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | - | 350 | ||||||
| Common Stock Shares Issued | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | ||||||
| Shares Outstanding | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialMersana Therapeutics, Inc. (MRSN) — SEC Financial Statements & Analysis
Mersana Therapeutics, Inc. (MRSN) is a pharmaceutical preparations company, incorporated in DE. Mersana Therapeutics, Inc. trades on Nasdaq as: MRSN. Mersana Therapeutics, Inc. (MRSN)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-14. Based on that filing, On profitability, Mersana Therapeutics, Inc. posts a gross margin of 110.68%, an operating margin of -196.61%, a net margin of -211.21%, a Return on Equity (ROE) of 239.64%, and a Return on Assets (ROA) of -60.36%. Per share, it reports EPS of $-14.04, diluted EPS of $-14.04, free cash flow per share of $-14.90, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -4.76% year-over-year, net income growth of -6.08% year-over-year, and EPS growth of -7.66% year-over-year. On the balance sheet, it maintains a current ratio of 1.39x, a quick ratio of 1.31x, working capital of $16.72M, a debt-to-equity ratio of -2.05x, a debt ratio of 1.95, an interest coverage ratio of -26.52x, free cash flow of $-74.37M (TTM), and net debt of $-56.87M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-14.04
- ROE TTM
- 239.64%
- ROA TTM
- -60.36%
- Debt To Equity
- -2.05x
- Free Cash Flow TTM
- $-74.37M
- Net Revenue TTM Growth 1Y
- -4.76%
Data as of 2025-09-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Mersana Therapeutics, Inc. in?
Mersana Therapeutics, Inc. (MRSN) operates in the Pharmaceutical Preparations industry.
What exchange does MRSN trade on?
Mersana Therapeutics, Inc. (MRSN) trades on the Nasdaq.
Where is Mersana Therapeutics, Inc. incorporated?
Mersana Therapeutics, Inc. is incorporated in DE.
When was Mersana Therapeutics, Inc. (MRSN)'s most recent SEC filing?
Mersana Therapeutics, Inc. (MRSN)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-14.
What is MRSN's EPS (earnings per share)?
Mersana Therapeutics, Inc. (MRSN)'s trailing twelve month EPS is $-14.04 as of 2025-09-30.
What is MRSN's ROE (return on equity)?
Mersana Therapeutics, Inc. (MRSN)'s trailing twelve month Return on Equity (ROE) is 239.64% as of 2025-09-30.
What is MRSN's ROA (return on assets)?
Mersana Therapeutics, Inc. (MRSN)'s trailing twelve month Return on Assets (ROA) is -60.36% as of 2025-09-30.